XOLAIR has been shown to significantly reduce exacerbations in appropriate allergic asthma patients uncontrolled on inhaled corticosteroids (ICS). 1

Multiple clinical studies were done to analyze the efficacy and safety of XOLAIR in 2 patient populations:

  1. Adolescent and adult patients aged ≥12 years. See data.
  2. Pediatric patients aged 6 to <12 years. See data.

See additional information for patient baseline characteristics. Please see full safety information

Adolescent & Adult Study Results (≥12 Years)

Pediatric Study Results (6 to <12 Years)

Patient Baseline Characteristics